Department of Medical Oncology, Enshi Tujia and Miao Autonomous Prefecture Central Hospital, 158 Wuyang Road, Enshi, 445000, Hubei, China.
Department of Pediatric Surgery, Enshi Tujia and Miao Autonomous Prefecture Central Hospital, 158 Wuyang Road, Enshi, 445000, Hubei, China.
BMC Gastroenterol. 2023 Nov 1;23(1):374. doi: 10.1186/s12876-023-03011-y.
This paper aimed to assess the clinical efficacy, adverse reactions, and safety of employing PD-1 inhibitors in conjunction with chemotherapy as a treatment strategy for advanced gastric cancer (GC).
Ninety patients with advanced GC from January 2020 to December 2021 were divided into the research group (n = 45) and the control group (n = 45). The control group was treated with apatinib and tigio. The study group was treated with PD-1 inhibitor combined with apatinib and tigio. The remission rate (RR), disease control rate (DCR), overall survival (OS), Eastern Oncology Collaborative Group Physical Status Assessment (ECOG-PS) score, EORTCQLQ-C30 (v3.0) score, and incidence of adverse reactions were compared between the two groups.
The research group exhibited improved outcomes in several key metrics relative to the control group. Specifically, the RR, DCR, and OS were notably higher in the research group. Additionally, the ECOG-PS score was significantly reduced, indicating better performance. At a median follow-up of 8.7 months, the research group's functional and total health scores on the EORTC QLQ-C30 (v3.0) scale had seen significant improvement compared to their initial scores and were also superior to the control group's scores. Importantly, both groups demonstrated comparable incidence rates for adverse reactions, with no significant difference observed (P > 0.05).
PD-1 inhibitor combined with chemotherapy was more effective when treating patients with advanced GC. It was more beneficial to enhance the patient's condition, promote survival time, and improve physical status and life quality. In addition, the adverse reactions could be controlled.
本研究旨在评估 PD-1 抑制剂联合化疗治疗晚期胃癌（GC）的临床疗效、不良反应和安全性。
2020 年 1 月至 2021 年 12 月，90 例晚期 GC 患者分为研究组（n=45）和对照组（n=45）。对照组给予阿帕替尼和替吉奥治疗，研究组给予 PD-1 抑制剂联合阿帕替尼和替吉奥治疗。比较两组缓解率（RR）、疾病控制率（DCR）、总生存期（OS）、东部肿瘤协作组体能状况评分（ECOG-PS）、欧洲癌症研究与治疗组织生活质量核心问卷 30 版（EORTCQLQ-C30，v3.0）评分和不良反应发生率。
研究组多项关键指标优于对照组，RR、DCR 和 OS 均显著升高，ECOG-PS 评分明显降低，功能和总健康状况评分显著提高。中位随访 8.7 个月，研究组 EORTCQLQ-C30（v3.0）量表的功能和总健康评分与基线相比显著改善，且优于对照组。两组不良反应发生率相当，差异无统计学意义（P＞0.05）。
PD-1 抑制剂联合化疗治疗晚期 GC 更有效，能更有利于改善患者病情，延长生存时间，提高生活质量和身体状况，且不良反应可控制。
